EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) Study Program
Latest Information Update: 18 Apr 2025
At a glance
- Drugs Empagliflozin (Primary) ; Albiglutide; Alogliptin; Dipeptidyl peptidase 4 inhibitors; Dulaglutide; Exenatide; Glucagon-like peptide-1 receptor agonists; Linagliptin; Liraglutide; Lixisenatide; Saxagliptin; Semaglutide; Sitagliptin
- Indications Cardiovascular disorders; Myocardial infarction; Stroke; Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Acronyms EMPRISE; EMPRISE United States
- Sponsors Boehringer Ingelheim
Most Recent Events
- 15 Apr 2025 Planned End Date changed from 30 Mar 2025 to 31 Dec 2025.
- 15 Apr 2025 Planned primary completion date changed from 30 Mar 2025 to 31 Dec 2025.
- 08 Jan 2025 Planned End Date changed from 31 Dec 2024 to 30 Mar 2025.